文献速递淋巴瘤

ROR1与BCR通路之间的串扰定义了套细胞淋巴瘤的新治疗策略

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2017-11-09

研究探讨套细胞淋巴瘤(MCL)中ROR1介导的凋亡反应差异的分子机制,发现靶向ROR1可下调NF-κB p65水平,而NF-κB通路激活可拮抗ROR1介导的凋亡。高通量药物敏感性检测显示,同时靶向ROR1与BCR或Bcl-2家族具有协同效应,但伊布替尼抑制BCR通路可能损害ROR1表达并影响ROR1靶向治疗,强调同时抑制两条通路的重要性。

要点

  • 靶向ROR1表达导致NF-κB p65水平下调,NF-κB通路激活可拮抗ROR1介导的凋亡反应。
  • 同时靶向ROR1与BCR或Bcl-2家族在MCL细胞中显示协同效应。
  • 伊布替尼抑制BCR通路可损害ROR1表达,可能影响ROR1靶向治疗效果。

核心结论

  • ROR1与BCR通路之间的串扰定义了MCL中新的治疗策略,同时抑制两条通路可能增强杀伤癌细胞。

研究设计与样本

  • 研究使用MCL细胞系和原代样本,进行高通量药物敏感性检测,比较ROR1靶向前后的药物反应。

主要发现

  • 靶向ROR1表达导致NF-κB p65水平下调,NF-κB通路激活可拮抗ROR1介导的凋亡反应。
  • 高通量药物敏感性检测显示,同时靶向ROR1与BCR或Bcl-2家族具有协同效应。
  • 伊布替尼抑制BCR通路可损害ROR1表达,从而可能影响ROR1靶向治疗。

临床怎么用

  • 作者认为,同时抑制ROR1和BCR通路可能增强对MCL癌细胞的杀伤作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin B-cell lymphoma with poor prognosis due to drug resistance. Introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has markedly improved MCL therapy outcome, but drug resistance remains a challenge. The selective cell-surface expression of oncogenic receptor tyrosine kinase-like orphan receptor 1 (ROR1) pseudokinase in hematological malignancies has made this receptor a promising candidate for targeted therapy. We sought to identify the molecular mechanism underlying divergent ROR1-mediated apoptotic responses in MCL cell lines and primary samples. We show that targeting ROR1 expression resulted in downregulation of NF-κB p65 levels and that activation of the NF-κB pathway can antagonize ROR1-mediated apoptotic responses. High-throughput drug-sensitivity testing of MCL cells before and after ROR1 targeting revealed synergistic effects between cotargeting of ROR1 and the B-cell antigen receptor (BCR) or Bcl-2 family, underlining the high potential for ROR1-targeted therapies in overcoming MCL drug resistance. However, inhibition of the BCR pathway by targeted drugs such as ibrutinib can impair ROR1 expression and consequently ROR1-targeted treatments, underscoring the importance of inhibiting both pathways to augment cancer cell killing. Considering the central role of NF-κB pathway activation in B-cell malignancies, this study highlights key factors that can modulate ROR1-targeted treatments in hematological cancers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karvonen H, Chiron D, Niininen W, et al. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Adv. 2017. PMID: 29296874. doi:10.1182/bloodadvances.2017010215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。